PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2016.5842018502488-494Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II StudyKi Sun Jung, Su Jin Lee, Se Hoon Park, Jae-Lyun Lee, Se-Hoon Lee, Jae Yun Lim, Jung Hun Kang, Suee Lee, Sun Young Rha, Kyung Hee Lee, Ho Young Kim, Ho Yeong Limhttp://www.e-crt.org/upload/pdf/crt-2016-584.pdf, http://www.e-crt.org/journal/view.php?doi=10.4143/crt.2016.584, http://www.e-crt.org/upload/pdf/crt-2016-584.pdf
Renal Cell Carcinoma10.1007/978-4-431-55531-5_132017319-332Treatment for Non-clear Cell Renal Cell CarcinomaMakoto Sumitomohttp://link.springer.com/content/pdf/10.1007/978-4-431-55531-5_13
Clinical Genitourinary Cancer10.1016/j.clgc.2018.05.0112018165e997-e1002A Multicenter Phase II Trial of Axitinib in Patients With Recurrent or Metastatic Non–clear-cell Renal Cell Carcinoma Who Had Failed Prior Treatment With TemsirolimusInkeun Park, Se Hoon Lee, Jae Lyun Leehttps://api.elsevier.com/content/article/PII:S1558767318301496?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1558767318301496?httpAccept=text/plain
European Urology10.1016/j.eururo.2021.03.0152021802162-170A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell CarcinomaThomas E. Hutson, M. Dror Michaelson, Timothy M. Kuzel, Neeraj Agarwal, Ana M. Molina, James J. Hsieh, Ulka N. Vaishampayan, Ran Xie, Urmi Bapat, Weifei Ye, Rohit K. Jain, Mayer N. Fishmanhttps://api.elsevier.com/content/article/PII:S030228382100213X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S030228382100213X?httpAccept=text/plain
Diseases of the Esophagus10.1093/dote/doab052.740202134Supplement_1740 CAMRELIZUMAB IN COMBINATION WITH PREOPERATIVE CHEMOTHERAPY FOR LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: A SINGLE-ARM, OPEN-LABEL, PHASE II STUDYFeng Wang, Yu Qi, Xiangrui Meng, Qingxia Fanhttp://academic.oup.com/dote/article-pdf/34/Supplement_1/doab052.740/40403398/doab052.740.pdf, http://academic.oup.com/dote/article-pdf/34/Supplement_1/doab052.740/40403398/doab052.740.pdf
Clinical Lung Cancer10.1016/j.cllc.2012.12.0032013144356-363Efficacy and Safety of Oral Topotecan and Bevacizumab Combination as Second-Line Treatment for Relapsed Small-Cell Lung Cancer: An Open-Label Multicenter Single-Arm Phase II StudyDavid R. Spigel, David M. Waterhouse, Steve Lane, Philippe Legenne, Kamal Bhatthttps://api.elsevier.com/content/article/PII:S1525730412002689?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525730412002689?httpAccept=text/plain
Clinical Genitourinary Cancer10.3816/cgc.2009.n.025200973E58-E65Safety and Efficacy of PF-3512676 for the Treatment of Stage IV Renal Cell Carcinoma: An Open-Label, Multicenter Phase I/II StudyJohn A. Thompson, Timothy Kuzel, Beverly J. Drucker, Walter J. Urba, Ronald M. Bukowskihttps://api.elsevier.com/content/article/PII:S1558767311700325?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1558767311700325?httpAccept=text/plain
Cancer Management and Research10.2147/cmar.s1892872019Volume 116543-6552<p>Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II study</p>Zhiwei Chen, Shengping Shen, Wenbo Shi, Gening Jiang, Xin Wang, Hong Jian, Zhen Zhou, Zhengping Ding, Shun Luhttps://www.dovepress.com/getfile.php?fileID=51201, https://www.dovepress.com/getfile.php?fileID=51201
Annals of Oncology10.1093/annonc/mdx371201728v295Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of metastatic renal cell carcinoma (SWITCH-II)M. Retz, J. Bedke, E. Herrmann, M-O. Grimm, U. Zimmermann, L. Müller, C. Leiber, D. Teber, M. Wirth, C. Bolenz, R. van Alphen, M. De Santis, A. Beeker, M. Frank, J.E. Gschwendhttps://api.elsevier.com/content/article/PII:S0923753420381199?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753420381199?httpAccept=text/plain, http://academic.oup.com/annonc/article-pdf/28/suppl_5/mdx371/19939894/mdx371.pdf
Annals of Oncology10.1093/annonc/mdv524.03201526ix71238O Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinomaM. Xie, C. He, J. Huanghttps://api.elsevier.com/content/article/PII:S0923753419463424?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0923753419463424?httpAccept=text/plain